*Packaging may vary based on availability.
Generic for Kenalog · Mid-potency cream · 30g
Triamcinolone acetonide 0.1% is a mid-potency fluorinated prescription steroid used in children from around age 2 for moderate eczema on the body. It’s the most prescribed topical steroid in the United States across all age groups, and its use in children for trunk and extremity involvement is well-established in pediatric dermatology.
Childhood eczema frequently involves the trunk, arms, legs, and the antecubital and popliteal fossae (inside elbows and behind knees). Low-potency steroids routinely can’t clear established flares at these sites; triamcinolone can — but only on those areas, never on the face, neck, or skin folds.
Triamcinolone is a fluorinated glucocorticoid — the fluorine atom increases receptor affinity and skin penetration compared with non-fluorinated compounds. That matters on the body, where the thicker stratum corneum needs more drug penetration to reach the inflammatory cells in the dermis. Once bound, it suppresses the NF-κB-driven cytokine cascade behind eczema inflammation.
The cream formulation penetrates well for the relatively moist, often weeping flares typical of pediatric body eczema. Twice-daily application maintains therapeutic drug concentrations in the skin throughout the day.
Triamcinolone 0.1% has extensive pediatric evidence as part of the broader topical corticosteroid literature, supplemented by direct pediatric trials. It appears in AAD, EADV, and BAD pediatric eczema guidelines as a standard mid-potency agent for body-site involvement. Multiple pediatric RCTs confirm its superiority over low-potency agents for moderate-to-severe eczema on the trunk and extremities.
The proactive twice-weekly maintenance strategy — applying to previously affected skin even when clear to prevent recurrence — has pediatric-specific evidence supporting its use in children with recurring body-site eczema.
Not for the face, neck, eyelids, or skin folds at any age. This is the most important restriction for parents to internalize. Children’s eczema frequently involves the face alongside body sites, and it’s tempting to use whatever works on all affected areas — but triamcinolone on a child’s face creates real atrophy risk. Use hydrocortisone 2.5% or desonide for facial involvement, and tacrolimus 0.03% for long-term facial maintenance.
Children’s higher surface-area-to-body-weight ratio means applying triamcinolone over a large percentage of a young child’s body carries a more meaningful systemic absorption risk than the same coverage in an adult. Short courses (7–14 days) on appropriate body sites have a well-established safety record. Extended use, large coverage areas, and occlusive clothing or bandages all increase risk. Your clinician should know the extent of your child’s involvement when prescribing.
| Traditional | With Fern | |
|---|---|---|
| Doctor appointment | ~30 days to book | 5-hour clinician review |
| Getting the Rx | Separate pharmacy trip | Shipped to your door |
| Cost | Insurance + copays | $35/mo, no insurance |
| Follow-up | Second appointment | Message the care team |
Most pediatric dermatologists use triamcinolone 0.1% in children from around age 2 for body-site involvement. In younger children (under 2), the surface-area-to-body-weight ratio and skin permeability are high enough that the risk-benefit calculation more often favors staying with low-potency options, even for body sites. Your Fern clinician will take your child’s age and the extent of involvement into account.
No. Use triamcinolone only on trunk and extremity (arm and leg) involvement. Use a low-potency steroid (hydrocortisone 2.5% or desonide) for facial and neck involvement, and a calcineurin inhibitor (tacrolimus 0.03%) for long-term facial maintenance. Widespread eczema in a child warrants clinician guidance on how to treat different areas simultaneously with appropriate-potency options.
The fingertip unit (FTU) is the standard guide — the amount from fingertip to first joint crease on an adult’s finger. For a 3–5 year old: 1 FTU for the trunk front or back; 1 FTU for the entire arm; 1.5 FTU for the entire leg. Use less for younger children. A common parent error is applying too much, which doesn’t increase efficacy but does increase absorption and systemic risk.
Clinically significant growth effects from appropriate short-course topical steroid use are very rare and not well-documented in the literature. Growth-related concerns are meaningful with systemic steroids (oral prednisone), not with topical use at standard amounts and areas. If you’re worried about long-term steroid exposure, that’s a good conversation to have with your clinician about transitioning to non-steroidal options (like tacrolimus) for ongoing maintenance.
Triamcinolone addresses the underlying inflammation, which drives the itch. Effective anti-inflammatory treatment typically reduces nighttime scratching significantly within the first week of a course. For persistent nocturnal itch even with effective topical management, hydroxyzine (the sedating antihistamine in the formulary) is specifically prescribed for this purpose.
Fern clinicians review every case individually. Most patients hear back in under 3 hours.
Start your child's assessment →This information is for educational purposes only and is not medical advice. Consult with a healthcare provider before starting any treatment.
“There’s a specific look I recognize in eczema patients who’ve been managing on their own too long. They’ve stopped believing it can get better. Fern shortens that window of suffering. It gets people into real treatment before hopelessness sets in.”